FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

omb Approval

OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Onyx Therapeutics, Inc.			2. Date of Event Requiring Statement (Month/Day/Year) 06/20/2018 3. Issuer Name and Ticker or Trading Symbol Kezar Life Sciences, Inc. [KZR]							
(Last) (First) (Middle) ONE AMGEN CENTER DRIVE				Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner		(Mo	5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Street) THOUSAND OAKS (City)	CA (State)	91320-1799 (Zip)			Officer (give title below)	Other (spec below)	App	olicable Line) Form filed by	/Group Filing (Check y One Reporting Person y More than One erson	
Table I - Non-Derivative Securities Beneficially Owned										
1. Title of Security (Instr. 4)				2. Amount of Securities Beneficially Owned (Instr. 4)			4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)										
1. Title of Derivative Security (Instr. 4)			2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise	Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)	
			Date Exercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security	Direct (D) or Indirect (I) (Instr. 5)		
Series A Redee Stock	emable Convert	ible Preferred	(1)	(1)	Common Stock	1,121,384	(1)	D ⁽²⁾⁽³⁾		
1. Name and Add	ress of Reporting	Person*								

1. Name and Address of Reporting Person* Onyx Therapeutics, Inc.								
(Last)	(First)	(Middle)						
ONE AMGEN CENTER DRIVE								
(Street)								
THOUSAND OAKS	CA	91320-1799						
(City)	(State)	(Zip)						
1. Name and Address of Reporting Person* AMGEN INC								
(Last)	(First)	(Middle)						
ONE AMGEN CENTER DRIVE								
(Street)								
THOUSAND OAKS	CA	91320-1799						
(City)	(State)	(Zip)						

Explanation of Responses:

- 1. As more fully described in the Issuer's Registration Statement on Form S-1 (Registration No. 333-225194), upon completion of the Issuer's initial public offering, each share of Series A redeemable convertible preferred stock will automatically convert into one share of the Issuer's common stock.
- 2. These shares are owned directly by Onyx Therapeutics, Inc., or Onyx, an indirect wholly-owned subsidiary of Amgen Inc., or Amgen. Amgen may be deemed to beneficially own securities held by Onyx, but disclaims beneficial ownership of the securities reported herein except to the extent of its pecuniary interest therein.
- 3. 10% beneficial ownership is calculated in accordance with SEC rules based on the number of shares of the Issuer's common stock outstanding on the date hereof and the conversion of only the reporting person's shares of preferred stock. Upon the closing of the Issuer's initial public offering, the shares held by the reporting persons will represent less than 10% beneficial ownership of the outstanding shares of common stock.

Remarks:

Onyx Therapeutics, Inc. and Amgen Inc.

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.